European CHMP recommends approval of new strength, pharmaceutical form and route of administration for natalizumab (Tysabri)

The new 150 mg solution for injection formulation will be licensed for subcutaneous use administration for the treatment of adults with highly active relapsing remitting multiple sclerosis.

Source:

European Medicines Agency